Evaluation of Strontium-Containing PCL-PDIPF Scaffolds for Bone Tissue Engineering: In Vitro and In Vivo Studies
Bone tissue engineering (BTE) has the general objective of restoring and improving damaged bone. A very interesting strategy for BTE is to combine an adequate polymeric scaffold with an osteoinductive compound. Strontium is a divalent cation that can substitute calcium in hydroxyapatite and induce both anabolic and anti-catabolic effects in bone. On the other hand, systemic increases in Sr2+ levels can provoke adverse cardiovascular effects. In the present study we have developed a compatibilized blend of poly-ε-caprolactone (PCL) and polydiisopropyl fumarate (PDIPF) enriched with 1% or 5% Sr2+ and evaluated the applicability of these biomaterials for BTE, both in vitro and in vivo. In vitro, whereas Blend + 5% Sr2+ was pro-inflammatory and anti-osteogenic, Blend + 1% Sr2+ released very low quantities of the cation; was not cytotoxic for cultured macrophages; and showed improved osteocompatibility when used as a substratum for primary cultures of bone marrow stromal cells. In vivo, implants with Blend + 1% Sr2+ significantly increased bone tissue regeneration and improved fibrous bridging (vs. Blend alone), while neither inducing a local inflammatory response nor increased serum levels of Sr2+. These results indicate that our compatibilized blend of PCL-PDIPF enriched with 1% Sr2+ could be useful for BTE.
KeywordsBone marrow stromal cells RAW 264.7 macrophages Poly-ε-caprolactone Polydiisopropyl fumarate Strontium Bone regeneration
ABL is a Fellow of Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. ADM is a part-time full Professor of Clinical Chemistry at National University of La Plata (UNLP), Argentina. JMF is a Member of the Carrera del Investigador of Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. This study was supported by ANPCyT grants (PICT 2012-0053 to ADM, PICT 2015-1361 to ADM and PICT 2015-1030 to JMF).
Conflict of interest
All authors declare that they have no conflicts of interest.
- 9.Denlinger, L. C., P. L. Fisette, K. A. Garis, G. Kwon, A. Vazquez-Torres, A. D. Simon, B. Nguyen, R. A. Proctor, P. J. Bertics, and J. A. Corbett. Regulation of inducible nitric oxide synthase expression by macrophage purinoreceptors and calcium. J. Biol. Chem. 271:337–342, 1996.CrossRefGoogle Scholar
- 10.European Medicines Agency. PRAC recommends suspending use of Protelos/Osseor (strontium ranelate). http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Protelos_and_Osseor/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500159374.pdf [10/06/2014].
- 17.Guidelines on Handling and Training of Laboratory Animals. Published by the Universities Federation for Animals Welfare Guidelines on Handling and Training of Laboratory Animals. In: The Biological Council of Animal Research, Welfare Panel. Guide for the Care and Use of Laboratory Animals: Eighth Edition, edited by Purl UFA. Washington, DC: The National Academies Press, 2011.Google Scholar
- 26.Molinuevo, M. S., J. M. Fernandez, A. M. Cortizo, A. D. McCarthy, L. Schurman, and C. Sedlinsky. Advanced glycation end products and strontium ranelate promote osteogenic differentiation of vascular smooth muscle cells in vitro: preventive role of vitamin D. Mol. Cell. Endocrinol. 450:94–104, 2017.CrossRefGoogle Scholar
- 31.Porter, J. R., T. T. Ruckh, and K. C. Popat. Bone tissue engineering: a review in bone biomimetics and drug delivery strategies. Biotechnol. Progr. 25:1539–1560, 2009.Google Scholar
- 33.Reginster, J. Y., E. Seeman, M. C. De Vernejoul, S. Adami, J. Compston, C. Phenekos, J. P. Devogelaer, M. D. Curiel, A. Sawicki, S. Goemaere, O. H. Sorensen, D. Felsenberg, and P. J. Meunier. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) Study. J. Clin. Endocrinol. Metab. 90:2816–2822, 2005.CrossRefGoogle Scholar